Mutations in CD8 that affect interactions with HLA class I and monoclonal anti-CD8 antibodies.
about
Reconstitution of the subclass-specific expression of CD4 in thymocytes and peripheral T cells of transgenic mice: identification of a human CD4 enhancerStructural Basis of the CD8 /MHC Class I Interaction: Focused Recognition Orients CD8 to a T Cell Proximal PositionThe CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC'C" face of the human CD2 adhesion domain.The role of charge and multiple faces of the CD8 alpha/alpha homodimer in binding to major histocompatibility complex class I molecules: support for a bivalent model.Familial CD8 deficiency due to a mutation in the CD8 alpha gene.The alpha 3 domain of the Qa-2 molecule is defective for CD8 binding and cytotoxic T lymphocyte activation.Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the alpha 2 and alpha 3 domains of MHC class I.Human CD8 transgene regulation of HLA recognition by murine T cells.Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex bindingIntraepithelial lymphocytes and their recognition of non-classical MHC molecules.Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.Recent advances in graft-versus-host disease (GVHD) prevention.Mutational analysis of the CD2/CD58 interaction: the binding site for CD58 lies on one face of the first domain of human CD2.The human poliovirus receptor. Receptor-virus interaction and parameters of disease specificity.Identification of the CD8 DE loop as a surface functional epitope. Implications for major histocompatibility complex class I binding and CD8 inhibitor design.
P2860
Q24680530-69C5A82B-D96B-4BCA-8D01-F76A3EFA41B2Q27656650-53572F7E-F1AC-49B9-B659-F26B056ABD88Q30194655-DE41235C-6B9E-4E07-B479-F3923E17B68EQ35069304-21793C3D-ACF1-4827-AEB4-49CA0C267A1AQ36167336-53285087-4934-436D-B732-C5A3D4EE4799Q36362623-EFFDEFAE-FAA7-44A1-80F9-4AA90A7ECB94Q36365379-298EBC8E-8F66-490E-9CA8-23E50B83C4F5Q36365522-5F74D960-C675-4DD9-B7F8-0066B9D74210Q36520103-31085A63-D76E-4EDD-90E0-A3F4C2D48C50Q40391545-898C9C5E-83A5-41F7-9328-DDE2A1DB9EA8Q41417560-616946F4-0B79-471C-BB4D-F3138AD7040DQ41561701-D41E0625-59CC-4EBE-BE38-5AFEE9ED44FBQ42633344-8E8CB2DD-2718-4D3B-815E-5224EE7F15B7Q45788025-BEDC913D-E262-4853-B004-05CBC49F0704Q47954431-02682ECA-67F6-4D1A-94C1-5AF7DF428242
P2860
Mutations in CD8 that affect interactions with HLA class I and monoclonal anti-CD8 antibodies.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@ast
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@en
type
label
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@ast
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@en
prefLabel
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@ast
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@en
P2093
P2860
P356
P1476
Mutations in CD8 that affect i ...... onoclonal anti-CD8 antibodies.
@en
P2093
P2860
P304
P356
10.1084/JEM.174.2.371
P407
P577
1991-08-01T00:00:00Z